Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Urology Associates, PC

Neither a doctor nor a teaching hospital

Research payments

$1,204,471

325 payments

Through program year 2025, Urology Associates, PC is reported as receiving $1,204,471 in research payments, across 325 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $643,513 4
2024 Research $135,465 4
2023 Research $411,226 305
2022 Research $10,928 8
2021 Research $952 1
2020 Research $2,387 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $775,532 7 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $407,060 309 payments
  3. Epizyme, Inc., $17,832 5 payments
  4. Exelixis Inc. $2,387 3 payments
  5. Urogen Pharma, Inc. $1,659 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. Open-label external control arm study of darolutamide plus A $398,215 301 payments
  2. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $385,281 1 payment
  3. a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $298,165 2 payments
  4. A Randomised,Double blind,Placebo controlled,Adaptive,Population Enrichment Phase III Study of AZD5305 in Men with Metastatic Castration sensitive Prostate Cancer Receiving Physician is Choice New Hormonal Agents $88,505 1 payment
  5. CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer $17,832 5 payments
  6. Darolutamide Roll Over Study $8,845 8 payments
  7. A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and Locally Advanced Urothelial Carcinoma Study (mUC) $3,581 3 payments
  8. Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) $2,387 3 payments
  9. A Phase 3, Single-Arm, Multicentre Study to Evaluate the Efficacy and Safety of Ugn-103, A Novel Formulation of Ugn-102, for the Treatment of Patients With Low-Grade (LG) Non-Muscles Invasive Bladder Cancer (Nimbc) at Intermediate-Risk (Ir) of Recurrence $1,659 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record